218 related articles for article (PubMed ID: 37659079)
21. Adrenergic differentiation and Ret expression in rat pheochromocytomas.
Powers JF; Picard KL; Nyska A; Tischler AS
Endocr Pathol; 2008; 19(1):9-16. PubMed ID: 18317952
[TBL] [Abstract][Full Text] [Related]
22. Loss of Tumour Suppressor TMEM127 Drives RET-mediated Transformation Through Disrupted Membrane Dynamics.
Walker TJ; Reyes-Alvarez E; Hyndman BD; Sugiyama MG; Oliveira LCB; Rekab AN; Crupi MJF; Cabral-Dias R; Guo Q; Dahia PLM; Richardson DS; Antonescu CN; Mulligan LM
bioRxiv; 2024 Apr; ():. PubMed ID: 37425958
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
[TBL] [Abstract][Full Text] [Related]
24. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options.
Vicha A; Musil Z; Pacak K
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):186-91. PubMed ID: 23481210
[TBL] [Abstract][Full Text] [Related]
25. The RET proto-oncogene in sporadic pheochromocytomas.
Takaya K; Yoshimasa T; Arai H; Tamura N; Miyamoto Y; Itoh H; Nakao K
Intern Med; 1996 Jun; 35(6):449-52. PubMed ID: 8835594
[TBL] [Abstract][Full Text] [Related]
26. Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma.
Flynn A; Dwight T; Harris J; Benn D; Zhou L; Hogg A; Catchpoole D; James P; Duncan EL; Trainer A; Gill AJ; Clifton-Bligh R; Hicks RJ; Tothill RW
J Clin Endocrinol Metab; 2016 Mar; 101(3):1034-43. PubMed ID: 26796762
[TBL] [Abstract][Full Text] [Related]
27. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
[TBL] [Abstract][Full Text] [Related]
28. First continuous human pheochromocytoma cell line: KNA. Biological, cytogenetic and molecular characterization of KNA cells.
Pfragner R; Behmel A; Smith DP; Ponder BA; Wirnsberger G; Rinner I; Porta S; Henn T; Niederle B
J Neurocytol; 1998 Mar; 27(3):175-86. PubMed ID: 10640177
[TBL] [Abstract][Full Text] [Related]
29. A novel RET gene mutation in a patient with apparently sporadic pheochromocytoma.
Scollo C; Russo M; De Gregorio L; Terranova R; Mangione E; Castoro C; Squatrito S; Pellegriti G
Endocr J; 2016; 63(1):87-91. PubMed ID: 26497911
[TBL] [Abstract][Full Text] [Related]
30. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
[TBL] [Abstract][Full Text] [Related]
31. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
32. Germinal mutations of RET, SDHB, SDHD, and VHL genes in patients with apparently sporadic pheochromocytomas and paragangliomas.
Krawczyk A; Hasse-Lazar K; Pawlaczek A; Szpak-Ulczok S; Krajewska J; Paliczka-Cieślak E; Jurecka-Lubieniecka B; Roskosz J; Chmielik E; Ziaja J; Cierpka L; Peczkowska M; Preibisz A; Januszewicz A; Otto M; Jarzab B
Endokrynol Pol; 2010; 61(1):43-8. PubMed ID: 20205103
[TBL] [Abstract][Full Text] [Related]
33. [Genetics of paragangliomas and pheochromocytomas].
Favier J; Gimenez-Roqueplo AP
Med Sci (Paris); 2012; 28(6-7):625-32. PubMed ID: 22805139
[TBL] [Abstract][Full Text] [Related]
34. Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update.
Armaiz-Pena G; Flores SK; Cheng ZM; Zhang X; Esquivel E; Poullard N; Vaidyanathan A; Liu Q; Michalek J; Santillan-Gomez AA; Liss M; Ahmadi S; Katselnik D; Maldonado E; Salgado SA; Jimenez C; Fishbein L; Hamidi O; Else T; Lechan R; Tischler AS; Benn DE; Dwight T; Clifton-Bligh R; Sanso G; Barontini M; Vincent D; Aronin N; Biondi B; Koops M; Bowhay-Carnes E; Gimenez-Roqueplo AP; Alvarez-Eslava A; Bruder JM; Kitano M; Burnichon N; Ding Y; Dahia PLM
J Clin Endocrinol Metab; 2021 Jan; 106(1):e350-e364. PubMed ID: 33051659
[TBL] [Abstract][Full Text] [Related]
35. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II.
Neumann HP; Eng C; Mulligan LM; Glavac D; Zäuner I; Ponder BA; Crossey PA; Maher ER; Brauch H
JAMA; 1995 Oct; 274(14):1149-51. PubMed ID: 7563486
[TBL] [Abstract][Full Text] [Related]
36. Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
Korpershoek E; Petri BJ; van Nederveen FH; Dinjens WN; Verhofstad AA; de Herder WW; Schmid S; Perren A; Komminoth P; de Krijger RR
Endocr Relat Cancer; 2007 Jun; 14(2):453-62. PubMed ID: 17639058
[TBL] [Abstract][Full Text] [Related]
37. The Tumour Suppressor TMEM127 Is a Nedd4-Family E3 Ligase Adaptor Required by Salmonella SteD to Ubiquitinate and Degrade MHC Class II Molecules.
Alix E; Godlee C; Cerny O; Blundell S; Tocci R; Matthews S; Liu M; Pruneda JN; Swatek KN; Komander D; Sleap T; Holden DW
Cell Host Microbe; 2020 Jul; 28(1):54-68.e7. PubMed ID: 32526160
[TBL] [Abstract][Full Text] [Related]
38. High levels of tyrosine phosphorylated proto-ret in sporadic phenochromocytomas.
Le Hir H; Colucci-D'Amato LG; Charlet-Berguerand N; Plouin PF; Bertagna X; de Franciscis V; Thermes C
Cancer Res; 2000 Mar; 60(5):1365-70. PubMed ID: 10728700
[TBL] [Abstract][Full Text] [Related]
39. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.
Favier J; Igaz P; Burnichon N; Amar L; Libé R; Badoual C; Tissier F; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP
Endocr Pathol; 2012 Mar; 23(1):34-42. PubMed ID: 22183643
[TBL] [Abstract][Full Text] [Related]
40. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma.
Abermil N; Guillaud-Bataille M; Burnichon N; Venisse A; Manivet P; Guignat L; Drui D; Chupin M; Josseaume C; Affres H; Plouin PF; Bertherat J; Jeunemaître X; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2012 May; 97(5):E805-9. PubMed ID: 22419703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
